Live Breaking News & Updates on Krys Lee|Page 7

Stay updated with breaking news from Krys lee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

HC Wainwright Increases Krystal Biotech (NASDAQ:KRYS) Price Target to $139.00

Krystal Biotech (NASDAQ:KRYS – Get Rating) had its price target boosted by HC Wainwright from $119.00 to $139.00 in a report released on Monday, The Fly reports. HC Wainwright also issued estimates for Krystal Biotech’s Q3 2023 earnings at ($1.02) EPS, Q4 2023 earnings at ($0.93) EPS, FY2023 earnings at ($4.90) EPS, FY2024 earnings at […] ....

United States , Daniel Janney , Stifel Nicolaus , Kathryn Romano , Gilder Gagnon Howe Co , Goldman Sachs Group , Geode Capital Management , International Biotechnology Trust , Krystal Biotech Company Profile , Capital Impact Advisors , Krystal Biotech Inc , Securities Exchange Commission , Capital Management , Krystal Biotech , Get Rating , Chardan Capital , Exchange Commission , Director Daniel Janney , Impact Advisors , Biotechnology Trust , Gagnon Howe , Krystal Biotech Daily , Nasdaq Krys , Boost Price Target , Hc Wainwright ,

Krystal Biotech (NASDAQ:KRYS) PT Raised to $148.00

Krystal Biotech (NASDAQ:KRYS – Get Rating) had its price target increased by Chardan Capital from $133.00 to $148.00 in a research report sent to investors on Monday morning, The Fly reports. Chardan Capital also issued estimates for Krystal Biotech’s FY2023 earnings at ($5.46) EPS and FY2024 earnings at $3.03 EPS. A number of other research […] ....

United States , Daniel Janney , Suma Krishnan , William Blair , Goldman Sachs Group , Metlife Investment Management , Krystal Biotech Inc , York Mellon Corp , Blackrock Inc , Great West Life Assurance Co , Securities Exchange Commission , Krystal Biotech , Get Rating , Chardan Capital , Biotech Stock Down , Director Daniel Janney , Exchange Commission , New York Mellon Corp , Life Investment Management , Great West Life Assurance , West Life Assurance , Krystal Biotech Daily , Nasdaq Krys , Boost Price Target ,

Krystal Biotech (NASDAQ:KRYS) PT Raised to $145.00

Krystal Biotech (NASDAQ:KRYS – Get Rating) had its price target raised by equities research analysts at Stifel Nicolaus from $102.00 to $145.00 in a report issued on Wednesday, The Fly reports. Stifel Nicolaus’ price objective suggests a potential upside of 23.52% from the stock’s current price. Other equities analysts have also recently issued reports about […] ....

United States , William Blair , Dinoa Rossi , Stifel Nicolaus , Daniel Janney , Stifel Nicolau , Almanack Investment Partners , Tower Research Capital , Cubist Systematic Strategies , Great West Life Assurance Co , Securities Exchange Commission , Allspring Global Investments Holdings , Krystal Biotech Inc , Krystal Biotech , Get Rating , Director Dino , Exchange Commission , Director Daniel Janney , Investment Partners , Global Investments Holdings , West Life Assurance , Research Capital , Krystal Biotech Daily , Nasdaq Krys , Boost Price Target ,

Guggenheim Boosts Krystal Biotech (NASDAQ:KRYS) Price Target to $130.00

Krystal Biotech (NASDAQ:KRYS – Get Rating) had its target price hoisted by Guggenheim from $101.00 to $130.00 in a research report released on Monday morning, The Fly reports. Other equities analysts also recently issued reports about the stock. Chardan Capital boosted their price target on shares of Krystal Biotech from $133.00 to $148.00 in a […] ....

United States , William Blair , Daniel Janney , Stifel Nicolaus , Suma Krishnan , Group Plc , Goldman Sachs Group , Krystal Biotech Company Profile , Manufacturers Life Insurance Company , Proshare Advisors , Krystal Biotech Inc , Allspring Global Investments Holdings , Krystal Biotech , Get Rating , Director Daniel Janney , Global Investments Holdings , State Retirement System , General Group Plc , Share Advisors , Krystal Biotech Daily , Nasdaq Krys , Boost Price Target ,

Citigroup Inc. Sells 21,063 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Citigroup Inc. cut its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) by 42.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 28,760 shares of the company’s stock after selling 21,063 shares during the quarter. Citigroup Inc.’s holdings in Krystal Biotech were worth $2,278,000 at the end of the […] ....

United States , Daniel Janney , Kathryn Romano , Stifel Nicolaus , Tower Research Capital , Bellevue Group , Krystal Biotech Inc , Dimensional Fund Advisors , Citigroup Inc , Goldman Sachs Group , Holdings Channel , Hennion Walsh Asset Management Inc , Metlife Investment Management , Krystal Biotech , Get Rating , Life Investment Management , Research Capital , Walsh Asset Management , Fund Advisors , Director Daniel Janney , Visit Holdingschannel , Krystal Biotech Daily , Nasdaq Krys , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,